Sustained-Release Magnesium Tablet for Type 2 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current magnesium supplements for treating type 2 diabetes often cause side effects and are not suitable for long-term use, especially in patients with renal failure, as they can lead to hypermagnesemia and kidney issues, and they do not maintain a consistent magnesium level without blood peaks.
Innovation Solution
A low-dose, sustained-release magnesium composition in tablet form, combining magnesium with a hydrophilic delay agent, hydrophobic delay agent, inert fillers, and a protective coating that slows down magnesium release at the gastric level, ensuring continuous absorption throughout the gastrointestinal tract without gastroresistant coating, thereby maintaining a stable magnesium level and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional magnesium supplements are used to treat type 2 diabetes, then magnesium deficiency is corrected, but side effects occur and hypermagnesemia risk increases
Solution Approach 1:
The magnesium supplement is segmented into multiple small doses released at different times throughout the day, rather than administered as a single large dose. This is achieved through a sustained-release tablet formulation that gradually releases magnesium over 24 hours, preventing blood peaks and maintaining stable magnesium levels while reducing side effects and hypermagnesemia risk.
Solution Approach 2:
The magnesium release profile is made dynamic by using a sustained-release formulation that adapts to the body's circadian rhythms. The tablet releases magnesium gradually over time rather than all at once, with the release rate controlled by the formulation's physical and chemical properties, thereby maintaining optimal magnesium levels without causing harmful peaks.
2Quantity of substance
If high-dose magnesium is administered to correct deficiency, then magnesium levels improve, but kidney issues and hypermagnesemia risk increase
Solution Approach 1:
Instead of administering a single large dose of magnesium that exceeds the body's immediate needs, the formulation uses partial action by releasing magnesium in small, controlled amounts throughout the day. This gradual partial delivery ensures sufficient magnesium correction while avoiding excessive accumulation that could harm the kidneys, especially in patients with renal failure.
3Speed
If immediate-release magnesium tablets are used, then magnesium is absorbed quickly, but blood peaks occur and intestinal tolerance decreases
Solution Approach 1:
The magnesium release is made periodic rather than immediate, with the sustained-release tablet delivering magnesium in small increments over 24 hours. This periodic action prevents the sudden blood peaks associated with immediate-release formulations while maintaining adequate absorption speed to correct deficiency, and simultaneously reduces intestinal irritation caused by high concentrations of magnesium in the gut.
4Duration of action of stationary object
If magnesium supplements are taken long-term to maintain deficiency correction, then magnesium levels remain stable, but accumulation of harmful effects occurs
Solution Approach 1:
The formulation provides continuous useful action by maintaining stable magnesium levels through sustained release over 24 hours. The tablet continuously delivers small amounts of magnesium throughout the day, preventing both deficiency and the harmful accumulation that would result from intermittent high-dose supplementation. This continuous action eliminates the buildup of side effects while maintaining optimal magnesium levels for long-term use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides a gradual and continuous release of magnesium, optimizing absorption in the ileum, reducing the risk of hypermagnesemia, and improving bioavailability and intestinal tolerance, making it suitable for long-term use in patients with type 2 diabetes and its complications.
Implementation Method 1
a gradual-release magnesium matrix, which forms in particular a core, said matrix comprising, or in particular consisting of, magnesium, a hydrophilic delay agent (B1), a hydrophobic delay agent (B2)
Implementation Method 2
said composition also comprising a coating, which is not a gastroresistant coating, but a protective coating which slows down the dissolution of the Mg at the gastric level
Implementation Method 3
optimizing absorption in the ileum, reducing the risk of hypermagnesemia, and improving bioavailability
Data Source
AI summary
The invention relates to a specific composition for oral administration of magnesium, for use in the treatment of type 2 diabetes or the complications thereof, in association with a composition for treating type 2 diabetes or the complications thereof.